Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GlaxoSmithKline plc
CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.
Keeping Track: New Nucala Indication; BMS’ Ide-Cel Clears Filing Hurdle; First Applications From Telix And ADC Therapeutics
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Seattle Genetics holds the award for fastest supplemental approval (11 days) and fastest new molecular entity approval (119 days) under the US FDA's RTOR program, according to the Pink Sheet's Performance Tracker.
With coronavirus cases again on the rise in many European countries, members of two EU parliamentary committees asked industry representatives to explain why details of COVID-19 vaccine supply agreements are being kept under wraps.
- Other Names / Subsidiaries
- ABR Development
- Corixa Corporation
- Fountain Acquisition Corporation
- Genelabs Technologies, Inc.
- GlycoVaxyn AG
- Human Genome Sciences, Inc.
- ID Biomedical Corporation
- Okairos AG
- PRAECIS Pharmaceuticals, Inc.
- Reliant Pharmaceuticals
- Sirtris Pharmaceuticals
- Sitari Pharmaceuticals, Inc.
- SmithKline Beecham
- Stiefel Laboratories, Inc.
- Tesaro, Inc.
- ViiV Healthcare